Evidence map›Paper›PMID 34856869›Full record

ArticleHuman vaccines & immunotherapeutics2021

Human papillomavirus (HPV) vaccination across a cascade of knowledge, willingness, and uptake among gay, bisexual, and other men who have sex with men in Canada's three largest cities.

R Grewal, S L Deeks, T A Hart, J Cox, A De Pokomandy, T Grennan, G Lambert, D Moore, F Coutlée, M Gaspar and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 4 countries.

R GrewalMAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada.ORCID 0000-0002-1922-2442
S L DeeksDalla Lana School of Public Health, University of Toronto, Toronto, Canada.
T A HartDalla Lana School of Public Health, University of Toronto, Toronto, Canada.ORCID 0000-0001-5107-7452
J CoxDepartment of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, Montréal, McGill University.ORCID 0000-0002-7041-1556
A De PokomandyDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada.ORCID 0000-0001-6809-1357
T GrennanBC Centre for Disease Control, Provincial Health Services Authority, Vancouver, Canada.
G LambertDirection régionale de santé publique, CIUSSS-Centre-Sud-de-l'Île-de-Montréal, Montréal, Canada.
D MooreDepartment of Medicine, University of British Columbia, Vancouver, Canada.
F CoutléeCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Canada.
M GasparDalla Lana School of Public Health, University of Toronto, Toronto, Canada.ORCID 0000-0002-9015-2838
C GeorgeDepartment of Exercise, Health, and Sport Sciences, University of Maine, Portland, USA.
D GraceDalla Lana School of Public Health, University of Toronto, Toronto, Canada.ORCID 0000-0002-9032-3959
J JollimoreCommunity-Based Research Centre, Vancouver, Canada.
N J LachowskyBC Centre for Excellence in HIV/AIDS, Vancouver, Canada.ORCID 0000-0002-6336-8780
R NisenbaumMAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada.
G OgilvieBC Centre for Disease Control, Provincial Health Services Authority, Vancouver, Canada.
C SauvageauFaculty of Medicine, Université Laval, Québec City, Canada.ORCID 0000-0002-4300-1658
D H S TanMAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada.
A YeungMAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada.ORCID 0000-0003-4301-8473
A N BurchellMAP Centre for Urban Health Solutions, Unity Health Toronto, Toronto, Canada.
3M (United States) · USUniversity of British Columbia · CACentre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal · CACenter for Health, Exercise and Sport Sciences · RSCentre Hospitalier de l’Université de Montréal · CACommunity Based Research Centre · CAHealth Solutions (Sweden) · SEMcGill University · CAUniversité Laval · CAUniversity of Toronto · CAUniversity of Victoria · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSome Canadian jurisdictions offer publicly funded HPV vaccine to gay, bisexual, and other men who have sex with men (GBM) aged ≤26 years. We characterized factors associated with being in different stages of HPV vaccination.

methodsEngage is a sexual health study of GBM in the three largest Canadian cities recruited via respondent driven sampling (RDS). We categorized participants as: (1) unaware of HPV vaccine, (2) undecided/unwilling to get vaccinated, (3) willing to get vaccinated, (4) vaccinated with one or more doses. Our RDS-II weighted analyses used multinomial logistic regression to identify factors associated with being in earlier stages of the cascade compared to Stage 4.

resultsAcross the cities, 26-40%, 7-14%, 33-39%, and 13-28% were in Stages 1 to 4, respectively. Compared to Stage 4, being in earlier stages of the cascade was associated with bisexual-identification (Stage 1: adjusted odds ratio[aOR] = 2.84, 95% confidence interval[CI] = 1.06-7.62; Stage 2: aOR = 3.09, 95%CI = 1.19-8.05), having immigrated to Canada (Stage 1: aOR = 1.79, 95%CI 1.07-2.99), preference to keep same-sex romantic relationships private (Stage 1: aOR = 1.25, 95% CI = 1.05-1.48; Stage 2: aOR = 1.24, 95%CI = 1.05-1.46), not receiving sexual health information (Stage 1: aOR = 0.31, 95% CI = 0.13-0.71; Stage 2: aOR = 0.27, 95%CI = 0.12-0.64), not accessing a health-care provider (Stage 2: aOR = 0.36, 95%CI = 0.15-0.83), and no past hepatitis A/B vaccination (Stage 1: aOR = 0.16, 95% CI = 0.09-0.30; Stage 2: aOR = 0.18, 95%CI = 0.09-0.35; Stage 3: aOR = 0.38, 95%CI = 0.21-0.61). DISCUSSION: Interventions are needed to reduce social and financial barriers, increase sexual health knowledge, and improve GBM-competent health-care access to increase vaccine uptake among GBM.

Indexed as

AlphapapillomavirusPapillomavirus InfectionsPapillomavirus VaccinesSexual and Gender MinoritiesCanadaCitiesHealth Knowledge, Attitudes, PracticeHomosexuality, MaleHumansMaleVaccinationPapillomavirus VaccinesbarriersfacilitatorsHuman papillomavirusknowledgemen who have sex with menprimary preventionpublicly funded programuptakewillingness

Identifiers

PMID34856869
PMCPMC8904029
OpenAlexW3215288534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.